Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29425858 | 0.87 | STAT3 (0.41) | STAT3 | |
| SCHEMBL31371996 | 0.82 | STAT3 (0.56) | STAT3 | |
| SCHEMBL13998201 | 0.82 | STAT3 (0.56) | STAT3 | |
| Sweroside SCHEMBL307117 | 0.68 | STAT3 (1.00) | STAT3 | |
| SCHEMBL14010720 | 0.65 | STAT3 (0.40) | STAT3 | |
| SCHEMBL14010917 | 0.59 | STAT3 (0.40) | STAT3 | |
| SCHEMBL8398637 | 0.55 | — | — | |
| SCHEMBL23855448 | 0.54 | HRH3 (0.33) | — | |
| SCHEMBL9181141 | 0.53 | BCL2L1 (0.35) | — | |
| SCHEMBL30874263 | 0.53 | MAOA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093288-B2 | Genipin derivatives and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100168160-A1 | Genipin Derivatives and Uses Thereof | BETH ISRAEL DEACONESS MEDICAL CENTER , INC. AND TRUSTEES OF BOSTON UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-7649014-B2 | Genipin derivatives and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
| US-20080009450-A9 | Genipin derivatives and uses thereof | ZHANG CHEN-YU | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | STAT3 3954/4885 |
| US-20080009450-A9 | Genipin derivatives and uses thereof | GPR119, PCK2, UCK2 | STAT3 3682/4885 |
| US-20100168160-A1 | Genipin Derivatives and Uses Thereof | GPR119, PCK2, UCK2 | STAT3 3682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.